Synthetically engineered bacteria destroys superbugs

By Admin
Scientists in Singapore have engineered a ‘suicide bomber strain of bacteria which has the ability to destroy a common but deadly hospital superb...

Scientists in Singapore have engineered a ‘suicide bomber’ strain of bacteria which has the ability to destroy a common but deadly hospital superbug.

The researchers have taken a strain of E.Coli which is commonly present in the human gut and empowered it to recognise and kill the Pseudomonas aeruginosa bacteria.

Upon recognising the superbug the newly engineered bacteria produces a fatal toxin, before exploding to cover the entire area in the chemical.   

It is thought this is the first time a study has used synthetic biology to tackle an infectious diseases.

READ MORE FROM THE WDM CONTENT NETWORK:

To read the latest edition of Healthcare Global, click here

Lab tests of the bacteria found it destroyed 99 percent of targets and it is now hoped it could be used to tackle drug-resistant superbugs and infections.  

Pseudomonas aeruginosa is often found in hospitals and targets patients with weakened immune systems.

The superbug can be fatal as it causes infections in any bodily tissues that it can attach itself too, including the lungs, guts and the bladder.

The results of the research have been published in the Molecular Systems Biology journal.

Share

Featured Articles

Philip Morris International (PMI) in agreement with KT&G

PMI and KT&G are building a smoke-free world. In a new agreement between the two companies, smoke-free alternatives are within reach for smokers

Health tech leader Philips shares sustainability ambition

Roy Jakobs, Royal Philips CEO, says the health technology company’s sustainability impact plan will ‘enhance accountability & strengthen talent’

Automating gene therapy & pharma discovery at Automata

Sonia Jassi, Drug Discovery & Synthetic Biology Lead at Automata, explains how automation increases efficiency in gene therapy laboratories

Itai Hayut, CEO of Scopio Labs, on AI & blood cancer

Technology & AI

2023 predictions with Harshit Jain, global CEO of Doceree

Telehealth & COVID-19

Wolters Kluwer Health: health equity and telehealth

Telehealth & COVID-19